Published in Biomark Insights on February 07, 2007
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med (2002) 27.55
The disease burden associated with overweight and obesity. JAMA (1999) 19.39
Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med (2002) 12.95
Heart failure. N Engl J Med (2003) 9.75
Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 8.49
Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet (1997) 6.48
A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci (1981) 6.39
Natriuretic peptides. N Engl J Med (1998) 6.04
Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet (2000) 6.01
Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA (2002) 5.19
Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation (1991) 4.89
How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J (1998) 4.48
Impact of obesity on plasma natriuretic peptide levels. Circulation (2004) 4.46
The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol (2005) 3.85
Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation (2004) 3.56
Wasting as independent risk factor for mortality in chronic heart failure. Lancet (1997) 3.37
The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J (2001) 3.07
Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol (2002) 3.05
Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation (2003) 2.97
NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J (2005) 2.93
Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation (1996) 2.59
Amino-terminal pro-brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. Ann Emerg Med (2006) 2.57
Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int (1979) 2.45
Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest (2006) 2.43
Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension (1996) 2.37
N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol (2003) 2.36
Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol (2005) 2.34
The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol (2001) 2.33
Physiological role of silent receptors of atrial natriuretic factor. Science (1987) 2.31
Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol (2004) 2.31
Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J (2005) 2.25
Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant (1996) 2.21
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation (1998) 2.17
Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol (2005) 2.05
N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA (2006) 2.04
Effect of obesity and being overweight on long-term mortality in congestive heart failure: influence of left ventricular systolic function. Eur Heart J (2004) 2.04
N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation (2004) 2.00
N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis (2005) 1.96
N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J (2003) 1.87
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A (2005) 1.85
Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol (2003) 1.81
Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol (2003) 1.80
Natriuretic peptide system in human heart failure. Circulation (1993) 1.79
Increased cardiac BNP expression associated with myocardial ischemia. FASEB J (2003) 1.78
B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis (2003) 1.74
B-type natriuretic peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device. Clin Chem (2004) 1.70
Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol (2004) 1.70
Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart. J Clin Invest (1989) 1.69
Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the breathing not properly multinational study. Ann Emerg Med (2005) 1.63
beta-Blocker therapy in heart failure: scientific review. JAMA (2002) 1.62
N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol (2002) 1.59
Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol (2005) 1.57
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol (2001) 1.54
Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology (2003) 1.40
Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest (1996) 1.39
Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation (2003) 1.38
A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem (1992) 1.34
Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. Eur Heart J (2003) 1.27
Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? J Am Coll Cardiol (2006) 1.25
Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail (2004) 1.24
Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J (2005) 1.24
Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart (2005) 1.24
Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Lond) (1995) 1.23
The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys (2006) 1.22
Assay for measurement of intact B-type natriuretic peptide prohormone in blood. Clin Chem (2006) 1.22
Natriuretic peptide receptor-C signaling and regulation. Peptides (2005) 1.21
Cardiac hormones as diagnostic tools in heart failure. Endocr Rev (2003) 1.20
Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol (2003) 1.20
Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med (2004) 1.19
Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J (1993) 1.19
Detection of exercise-induced ischemia by changes in B-type natriuretic peptides. J Am Coll Cardiol (2004) 1.19
Regulation of glomerular filtration rate in chronic congestive heart failure patients. Kidney Int (1988) 1.18
Acute myocardial hypoxia increases BNP gene expression. FASEB J (2004) 1.12
Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol (2000) 1.12
Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem (2005) 1.12
Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation (1999) 1.12
Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med (2004) 1.12
Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med (2006) 1.05
Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure. Cardiovasc Res (2004) 1.03
N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J (2003) 1.02
N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail (2004) 1.01
N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum (2003) 1.01
NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J (2006) 0.99
Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am J Cardiol (2005) 0.98
Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol (2004) 0.95
Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. Am J Cardiol (2004) 0.95
Molecular biology of natriuretic peptides and nitric oxide synthases. Cardiovasc Res (2001) 0.94
N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail (2004) 0.94
Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol (2006) 0.93
Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest (1998) 0.93
Is brain natriuretic peptide production decreased in obese subjects? J Am Coll Cardiol (2006) 0.91
Kidneys extract BNP and NT-proBNP in healthy young men. J Appl Physiol (1985) (2005) 0.90
BNP and N-terminal proBNP are both extracted in the normal kidney. Eur J Clin Invest (2006) 0.89
Isolated diastolic heart failure as a cause of breathlessness in the community: the Arbroath study. Eur J Heart Fail (2001) 0.88
Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation (2002) 0.87
Serum N-terminal pro-BNP levels correlate with symptoms and echocardiographic findings in patients with mitral stenosis. Echocardiography (2005) 0.86